Reagents that bind ccx-ckr2

Abstract

Antibodies that bind to CCX-CKR2 and methods of their use are provided.

1 . An antibody that competitively inhibits binding of a competitor antibody to CCX-CKR2, wherein the competitor antibody comprises the complementarity determining region (CDR) of:
 SEQ ID NO:12 and SEQ ID NO:14; or   SEQ ID NO:16 and SEQ ID NO:18.   
     
     
         2 . The antibody of  claim 1 , wherein the antibody is linked to a detectable label. 
     
     
         3 . The antibody of  claim 1 , which is a monoclonal antibody. 
     
     
         4 . The antibody of  claim 1 , which is a humanized antibody. 
     
     
         5 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of  claim 1 . 
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein the antibody is a monoclonal antibody. 
     
     
         7 . The pharmaceutical composition of  claim 5 , wherein the antibody is a humanized antibody. 
     
     
         8 . The pharmaceutical composition of  claim 5 , wherein the antibody comprises the complementarity determining regions (CDRs) of SEQ ID NO:12 and SEQ ID NO:14. 
     
     
         9 . The pharmaceutical composition of  claim 5 , wherein the antibody comprises SEQ ID NO:12 and SEQ ID NO:14. 
     
     
         10 . The pharmaceutical composition of  claim 5 , wherein the antibody comprises the complementarity determining regions (CDRs) of SEQ ID NO:16 and SEQ ID NO:18. 
     
     
         11 . The pharmaceutical composition of  claim 5 , wherein the antibody comprises SEQ ID NO:16 and SEQ ID NO:18. 
     
     
         12 . A method of inhibiting angiogenesis or proliferation of a cancer cell, the method comprising the step of contacting the cell with an antibody of  claim 1 . 
     
     
         13 . The method of  claim 12 , wherein the cell is in an individual. 
     
     
         14 . The method of  claim 13 , wherein the individual has or is pre-disposed to have arthritis. 
     
     
         15 . The method of  claim 13 , wherein the individual is not a human. 
     
     
         16 . A method for identifying a modulator of CCX CKR2, comprising:
 (a) combining a cell expressing a CCX CKR2 polypeptide or an extract of the cell with a test agent; and   (b) conducting an assay to detect whether the test agent competes with a competitor antibody for binding to the CCX CKR2 polypeptide, wherein the competitor antibody comprises the complementarity determining region (CDR) of:   SEQ ID NO:12 and SEQ ID NO:14; or   SEQ ID NO:16 and SEQ ID NO:18,   wherein competition between the competitor antibody and the test agent for binding to the CCX-CKR2 polypeptide is an indication that the test agent is a modulator of CCX CKR2 activity.   
     
     
         17 . A method for testing the efficacy of a test agent that modulates CCX-CKR2 activity, the method comprising,
 (a) administering the test reagent to a first animal;   (b) administering to a second animal an antibody that competes with a competitor antibody for binding to the CCX CKR2 polypeptide, wherein the competitor antibody comprises the complementarity determining region (CDR) of:   SEQ ID NO:12 and SEQ ID NO:14; or   SEQ ID NO:16 and SEQ ID NO:18; and   (c) comparing the effect of the test reagent on the first animal to the effect of the antibody on the second antibody, thereby determining the efficacy of a test agent.   
     
     
         18 . A polynucleotide encoding SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:18. 
     
     
         19 . The polynucleotide of  claim 18 , wherein the polynucleotide comprises SEQ ID NO:11,SEQ ID NO:13, SEQ ID NO:15, or SEQ ID NO:17. 
     
     
         20 . A method of producing a chimeric antibody, the method comprising operably linking a polynucleotide encoding at least one complementarity determining region (CDR) from SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:18 to a heterologous polynucleotide encoding at least the framework region of a heavy or light chain of an antibody, to form a fusion polynucleotide encoding a chimeric heavy or light chain of an antibody; and
 expressing a chimeric heavy or light chain from the fusion polynucleotide.